All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA clears investigational new drug application for ‘OncoMimic’ based immunotherapy EO2463
By Ellen Jenner
Bookmark this article
On March 24, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for EO2463, an ‘OncoMimic’ based immunotherapy being investigated for the treatment of indolent non-Hodgkin lymphoma.
A phase I/II clinical trial (NCT04669171), expected to be initiated in Q2 2021, will evaluate the safety, tolerability, and efficacy of EO2463 as a monotherapy and in combination with standard of care (rituximab, and rituximab plus lenalidomide) in 60 patients with follicular lymphoma and marginal zone lymphoma.
EO2463
EO2463 is a novel investigational immunotherapy that comprises four peptides, derived from bacteria present in the gut microbiome, which mimic B lymphocyte-specific lineage markers. The ‘OncoMimic’ based therapy is designed to induce full depletion of the malignant B lymphocytes that are enriched in indolent non-Hodgkin lymphoma.
- Enterome. Enterome receives FDA IND clearance for EO2463, an ‘OncoMimic’ based immunotherapy targeting liquid tumors. https://www.enterome.com/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors/. Published Mar 24, 2021. Accessed Mar 26, 2021.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox